5-HT6 Medicinal Chemistry

International Review of Neurobiology

Volumn 94, Issue C, 2010, Pages 1-34

  Liu, Kevin G ^a   Robichaud, Albert J ^a  

^a LUNDBECK RESEARCH USA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

1 BENZENESULFONYL 5 METHOXY N,N DIMETHYLTRYPTAMINE; 4 AMINO N [2,6 BIS(METHYLAMINO) 4 PYRIDINYL]BENZENESULFONAMIDE; 4 AMINO N [2,6 BIS(METHYLAMINO) 4 PYRIMIDINYL]BENZENESULFONAMIDE; 5 CHLORO N [4 METHOXY 3 (1 PIPERAZINYL)PHENYL] 3 METHYL 2 BENZOTHIOPHENESULFONAMIDE; 5 METHOXYTRYPTAMINE; ALX 1161; AZAINDAZOLE DERIVATIVE; AZAINDOLE DERIVATIVE; BENZIMIDAZOLE DERIVATIVE; BENZOFURAN DERIVATIVE; BENZOTHIAPHENE DERIVATIVE; INDAZOLE DERIVATIVE; INDOLE DERIVATIVE; ISOQUINOLINE DERIVATIVE; N (3,5 DICHLORO 2 METHOXYPHENYL) 4 METHOXY 3 (1 PIPERAZINYL)BENZENESULFONAMIDE; NAPHTHALENE DERIVATIVE; PYRAZOLOTRIAZINE DERIVATIVE; QUINOLINE DERIVATIVE; SB 214111; SB 257134; SB 258510; SEROTONIN 6 ANTAGONIST; SEROTONIN 6 RECEPTOR; SEROTONIN AGONIST; SEROTONIN ANTAGONIST; SEROTONIN RECEPTOR AFFECTING AGENT; SULFONAMIDE; SULFONE; THIENOPYRROLE DERIVATIVE; UNCLASSIFIED DRUG; UNINDEXED DRUG; AGENTS INTERACTING WITH TRANSMITTER, HORMONE OR DRUG RECEPTORS; SEROTONIN RECEPTOR;

BOOK; DOSE RESPONSE; DRUG BIOAVAILABILITY; DRUG HALF LIFE; DRUG MECHANISM; DRUG PENETRATION; DRUG POTENCY; DRUG RESEARCH; DRUG SCREENING; DRUG STRUCTURE; HUMAN; NONHUMAN; PRIORITY JOURNAL; PROTEIN FUNCTION; PROTEIN STRUCTURE; STRUCTURE ACTIVITY RELATION; ANIMAL; BRAIN LEVEL; CHEMISTRY; DRUG ANTAGONISM; DRUG EFFECT; DRUG POTENTIATION; METHODOLOGY; NEUROPHARMACOLOGY; PHYSIOLOGY; REVIEW; SIGNAL TRANSDUCTION;

ANIMALS; BRAIN CHEMISTRY; HUMANS; NEUROPHARMACOLOGY; NEUROTRANSMITTER AGENTS; RECEPTORS, SEROTONIN; SIGNAL TRANSDUCTION;

EID: 84942523329     PISSN: 00747742     EISSN: None     Source Type: Book Series    
DOI: 10.1016/B978-0-12-384976-2.00001-0     Document Type: Chapter

References (171)

1. 6 receptors. Bio. Med. Chem. Lett. 2005, 15:3510-3513.
2. 6 receptor antagonists. Bioorg. Med. Chem. Lett. 2005, 15:4867-4871.
3. Ahmed, M., Giblin, G. M. P., Johnson, C. N., Livermore, D. G. H., Miller, N. D., Moss, S. F., and Witty, D.R. (2007). Quinoline compounds capable of binding the CB2 and/or the 5-HT6 receptor, processes for preparing them, and pharmaceutical compositions containing them (65 pp.). WO Patent 2007039219.
4. Ahmed, M., Johnson, C. N., Jones, M. C., MacDonald, G. J., Moss, S. F., Thompson, M., Wade, C. E., and Witty, D. (2003). Preparation of arylsulfonyl(diazacycloalkyl)quinolines for treatment of CNS disorders (48 pp.). WO Patent 2003080580.
5. Johansson, G., Brandt, P., and Nilsson, B. M. (2005). Preparation of benzofuran derivatives that can be used in prophylaxis or treatment of 5-HT6 receptor-related disorders like obesity (231 pp.). WO Patent 2005058858.
6. Ahmed, M., Johnson, C. N., Miller, N. D., Trani, G., and Witty, D. R. (2005b). Preparation of 3-[(hetero)arylsulfonyl]-8-[(aminoalkyl)oxy]quinolines as 5-HT6 receptor antagonists for the treatment of CNS disorders (34 pp.). WO Patent 2005095346.
7. 6 Serotonin Receptor Agonists. J. Med. Chem. 2009, 52:675-687.
8. 6 antagonist, reverses cognitive impairment induced by subchronic phencyclidine in a novel object recognition test in rats. Int. J. Neuropsychopharmacol. 2010, 13:1021-1033.
9. Beard, C. C., Clark, R. D., Fisher, L. E., Harris, R. N. III, and Repke, D. B. (2002). Preparation of new indole derivatives with 5-HT6 receptor affinity (68 pp.). WO Patent 2002098857.
10. Becker, O., Lobera, M., Melendez, R. E., Sharadendu, A., Wu, L., Yu, X. Y., Dhanoa, D. S., Cheruku, S. R., Marantz, Y., Noiman, S., Fichman, M., Senderowitz, H., Shacham, S., Saha, A., and Orbach, P. (2006). Preparation of piperazinylarylamines as 5-HT6 modulators (169 pp.). WO Patent 2006081332.
11. 6 receptor antagonist, Ro 04-6790, in rats. Br. J. Pharmacol. 1999, 126:1537-1542.
12. Berger, J., Clark, R. D., and Zhao, S.-H. (2003a). Preparation of benzoxazines as 5-HT6 modulators (67 pp.). WO Patent 2003095434.
13. Berger, J., Clark, R. D., and Zhao, S. H. (2003b). Preparation of 1-[2-alkoxy-5-(arylsulfonyl)phenyl]piperazines with 5-HT6 receptor affinity (37 pp.). WO Patent 2003014097.
14. 6 receptor ligands. Bioorg. Med. Chem. Lett. 2004, 14:5499-5502.
15. 6 receptor ligands. Bioorg. Med. Chem. Lett. 2009, 19:6935-6938.
16. 6 receptor modulators. Bioorg. Med. Chem. Lett. 2010, 20:1657-1660.
17. 6 agonists. Bioorg. Med. Chem. 2009, 17:5153-5163.
18. Bernotas, R. C., and Yan, Y. (2004). Heterocyclyl-3-sulfonylazaindole or-azaindazole derivatives as 5-HT6 receptor ligands, and their use for the treatment of central nervous system disorders (18 pp.). US Patent 2004167030.
19. Bernotas, R. C., Yan, Y., Robichaud, A. J., and Liu, G. (2004b). Preparation of heterocyclyl-3-sulfonylindazoles as 5-hydroxytryptamine-6 ligands (31 pp.). US Patent 2004167122.
20. Boes M., Jenck F., Martin J.R., Moreau J.-L., Sleight A.J., Wichmann J., Widmer U. Novel agonists of 5HT2C receptors. Synthesis and biological evaluation of substituted 2-(Indol-1-yl)-1-methylethylamines and 2-(Indeno[1,2-b]pyrrol-1-yl)-1-methylethylamines. Improved therapeutics for obsessive compulsive disorder. J. Med. Chem. 1997, 40:2762-2769.
21. Boes, M., Riemer, C., and Stadler, H. (1999). Preparation of pyrazolopyrimidines and pyrazolotriazines with 5HT-6 receptor affinity (48 pp.). EP Patent 941994.
22. 6 receptor-selective radioligand [3H]Ro 63-0563 labels 5-hydroxytryptamine receptor binding sites in rat and porcine striatum. Mol. Pharmacol. 1998, 54:577-583.
23. Bonhaus, D. W., and Martin, R. S. (2006). Compositions and methods using 5-HT6 receptor antagonists and 5-HT2A receptor antagonists for treating cognitive disorders (25 pp.). WO Patent 2006069094.
24. 6 receptor antagonists, lead-optimization and biological evaluation of N-aryl and N-heteroaryl 4-amino-benzene sulfonamides. Eur. J. Med. Chem. 2001, 36:165-178.
25. 6 receptor in the rat brain, a study using antisense oligonucleotides. J. Pharmacol. Exp. Ther. 1995, 274:173-180.
26. Briggs, A. J., Clark, R. D., Harris, R. N. III, Repke, D. B., and Wren, D. L. (2002). Preparation of 4-piperazinylindoles with 5-HT6 receptor affinity (50 pp.). WO Patent 2002102774.
27. 6 receptor antagonists. Spec. Pub. R. Soc. Chem. 2001, 264:101-119.
28. Bromidge, S. M. (2002). Preparation of 4-piperazinoindoles for treating CNS disorders (44 pp). WO Patent 2002041889.
29. 6 receptor antagonist. J. Med. Chem. 1999, 42:202-205.
30. 6 antagonists, identification of N-(2,5-dibromo-3-fluorophenyl)-4-methoxy-3-piperazin-1-ylbenzenesulfonamide (SB-357134). Bioorg. Med. Chem. Lett. 2001, 11:55-58.
31. 6 receptor antagonists. Bioorg. Med. Chem. Lett. 2002, 12:1357-1360.
32. 6 receptor. Bioorg. Med. Chem. Lett. 2001, 11:2843-2846.
33. Bromidge, S. M., Johnson, C. N., MacDonald, G. J., Thompson, M., and Witty, D. R. (2003a). Preparation of 3-arylsulfonyl-7-piperazinyl- indoles, -benzofurans and -benzothiophenes with 5-HT6 receptor affinity for treating CNS disorders (30 pp.). WO Patent 2003013510.
34. Bromidge, S. M., Johnson, C. N., Moss, S. F., Rahman, S. S., and Witty, D. R. (2003b). Preparation of 7-arylsulfonamido-2,3,4,5-tetrahydro-1H-benzo[d]azepines with 5-HT6 receptor affinity for the treatment of CNS disorders (25 pp.). WO Patent 2003068751.
35. Bromidge, S. M., and Moss, S. F. (2002c). Preparation of benzo[d]azepines as 5-HT6 receptor antagonists (19 pp.). WO Patent 2002089811.
36. Caldirola, P., Johansson, G., and Nilsson, B. M. (2002). 2-, 3-, 4-, or 5-substituted-1-(benzenesulfonyl)indoles and their use in therapy (79 pp.). WO Patent 2002032863.
37. Caldirola, P., Johansson, G., and Sutin, L. (2006). Benzofuranyl derivatives as 5-HT6 receptor inhibitors, and therapeutic uses (26 pp.). WO Patent 2006134150.
38. Castagnoli, C., Gentile, G., and Payne, A. H. (2005). Preparation of 7-[4-(3-fluoro-4-methylbenzyl)benzenesulfonyl]-8-methoxy-3-methyl-2,3,4,5-tetrahydro-1H-3-benzazepine and related pharmaceutical salt compounds as antipsychotic agents (40 pp.). WO Patent 2005051399.
39. 6 serotonin receptor ligands. Bioorg. Med. Chem. Lett. 2004, 14:1961-1964.
40. Chu, C., Lister, A., Nordvall, G., Petersson, C., Rotticci, D., and Sohn, D. (2006). Preparation of 8-sulfonylamino-3-amino-substituted chroman or tetrahydronaphthalene derivatives modulating the 5HT6 receptor for treating Alzheimer's disease, cognitive impairment associated with schizophrenia, obesity and/or Parkinson's disease (146 pp.). WO Patent 2006126939.
41. Cole, D. C. (2005). Preparation of N-sulfonylheterocyclopyrrolylalkylamine compounds as 5-hydroxytryptamine-6 ligands (52 pp.). WO Patent 2005012311.
42. Cole, D. C., and Asselin, M. (2005) Sulfonyltetrahydro-3H-benzo(E)indole-8-amine compounds as 5-hydroxytryptamine-6 ligands. US patent 2005/0101596.
43. Cole, D. C., and Bernotas, R. C. (2005). Preparation of arylsulfonyldihydrobenzimidazolones as serotonin 5-HT6 receptor ligands (20 pp.). US Patent 2005020575.
44. 6 receptor antagonists. Bioorg. Med. Chem. Lett. 2005, 15:379-383.
45. Cole, D. C., Kelly, M. G., Bravo, B. A., and Palmer, Y. L. (2003). Preparation of 1-(indol-3-yl)alkylidenehydrazine carboximidamides as 5-hydroxytryptamine-6 ligands (27 pp.). WO Patent 2003232843.
46. 6 Receptor Agonists and Antagonists. J. Med. Chem. 2005, 48:353-356.
47. 6 receptor antagonists. Bio. Med. Chem. Lett. 2005, 15:4780-4785.
48. (6) receptor agonist. J. Med. Chem. 2007, 50:5535-5538.
49. Comery, T. A., and Schechter, L. E. (2007). Method using a combination of an acetylcholinesterase inhibitor and a 5-HT6 antagonist for the treatment of cognitive dysfunction (15 pp.). WO Patent 2007167431.
50. Conticello, R., Liu, R., Tehim, A., and Xie, W. (2010a). Preparation of pyrrolo[3,2-b]pyridine compounds with affinity for 5-HT6 receptors for treating CNS disorders, memory/cognitive impairment disorders, and GI disorders (41 pp.). WO Patent 2010024980.
51. Conticello, R., Liu, R., Tehim, A., and Xie, W. (2010b). Preparation of pyrrolo[3,2-b]pyridine piperazine compounds with affinity for 5-HT6 receptors for treating CNS disorders, memory/cognitive impairment disorders, and GI disorders (94 pp.). WO Patent 2010008832.
52. Cooper, D. G., Forbes, I. T., Garzya, V., Gribble, A. D., Lightfoot, A. P., Payne, A. H., and Smith, A. B. (2005a). Preparation of 7-heteroarylsulfonyl-tetrahydro-3-benzazepine derivatives as antipsychotic agents (38 pp.). WO Patent 2005025576.
53. Cooper, D. G., Forbes, I. T., Garzya, V., Gribble, A. D., Lightfoot, A. P., Payne, A. H., and Walker, G. (2005b). Piperidinyl- and piperazinyl-substituted phenylsulfonyl benzazepine compounds as antipsychotic agents and their preparation, pharmaceutical compositions, and use (46 pp.). WO Patent 2005014578.
54. Danca, M. D., Dunn, R., Tehim, A., and Xie, W. (2010). Preparation of pyrrolidine-substituted azaindole compounds having 5-HT6 receptor affinity for treatment of CNS disorders (56 pp.). US Patent 2010022581.
55. 6 receptor antagonists. Molecular mechanisms of receptor inactivation. J. Med. Chem. 2010, 53:1357-1369.
56. 6 receptor antagonist 2001.
57. Dunn, R., Nguyen, T. M., Xie, W., and Tehim, A. (2007). Preparation of heterocyclic compounds having 5-HT6 receptor affinity for treating CNS, gastrointestinal, and polyglutamine-repeat disorders (179 pp.). WO Patent 2007098418.
58. Dunn, R., Xie, W., and Tehim, A. (2009). Preparation of 3-substituted pyrrolo[3,2-b]pyridines having 5-HT6 receptor affinity (162 pp.). WO Patent 2009023844.
59. Spinks, D., Armer, R. E., Miller, D. J., Rankovic, Z., Spinks, G., Mestres, J., and Jaap, D. R. (2003). Preparation of 1-arylsulfonyl-3-substituted indoles and indolines for the treatment of central nervous system disorders (41 pp.). WO Patent 2003068220.
60. Dykes, G. (2006). Preparation of piperazinylbenzofurans for the treatment of obesity, type II diabetes, and CNS disorders (72 pp.). WO Patent 2006062481.
61. Elokdah, H. M., Greenfield, A. A., Liu, K., McDevitt, R. E., McFarlane, G. R., Grosanu, C., Lo, J. R., Li, Y., Robichaud, A. J., and Bernotas, R. C. (2007a). Preparation of substituted-3-sulfonylindazole derivatives as 5-HT6 receptor modulators for treating CNS disorders (109 pp.). US Patent 2007037802.
62. Elokdah, H. M., Greenfield, A. A., Liu, K., McFarlane, G. R., Grosanu, C., Lo, J. R., and Robichaud, A. J. (2007b). Preparation of azinyl-3-sulfonylindazole derivatives as 5-hydroxytryptamine-6 ligands (40 pp.). US Patent 2007054896.
63. Elokdah, H., Robichaud, A. J., Li, D. Z., McFarlane, G. R., Bernotas, R. C., Tawa, G. J., Zhang, G. M., Smith, D. L., and Schechter, L. E. (2005). Novel 1-(azacyclyl)-3-arylsulfonyl-1H-pyrrolo[2,3-b]pyridines as 5-HT6 agonists and antagonists. Abstracts of Papers, 230th ACS National Meeting, Washington, DC, United States, August 28-September 1, MEDI-115.
64. Filla, S. A., Flaugh, M. E., Gillig, J. R., Heinz, L. J., Krushinski, J. H.Jr., Liu, B., Pineiro-Nunez, M. M., Schaus, J. M., and Ward, J. S. (2002). Preparation of benzenesulfonic acid indol-5-yl esters as antagonists of the 5-HT6 receptor (125 pp.). WO Patent 2002060871.
65. 6 receptor modulation by E-6837 induces hypophagia and sustained weight loss in diet-induced obese rats. Br. J. Pharmacol. 2006, 148:973-983.
66. Forbes, I. T., Gentile, G., Gribble, A. D., Lightfoot, A. P., Payne, A. H., and Smith, A. B. (2005). Preparation of 7-phenylsulfonyl-tetrahydro-3-benzazepine derivatives as antipsychotic agents (40 pp.). WO Patent 2005051398.
67. Forbes, I. T., Gribble, A. D., Lightfoot, A. P., and Payne, A. H. (2004). Preparation of benzazepinyl thienylsulfonamide derivatives as antipsychotic agents (33 pp.). WO Patent 2004031181.
68. Fu, J.-M. (2003a). Preparation of 5-(arylsulfonyl)indoles having 5-HT6 receptor affinity for treatment of CNS disorders (98 pp.). WO Patent 2003011284.
69. Fu, J.-M. (2003b). Preparation of arylsulphonyl-substituted tetrahydro- and hexahydrocarbazolamines as 5-HT6 receptor ligands (66 pp.). WO Patent 2003030901.
70. Garzya V., Forbes I.T., Gribble A.D., Hadley M.S., Lightfoot A.P., Payne A.H., Smith A.B., Douglas S.E., Cooper D.G., Stansfield I.G., Meeson M., Dodds E.E., Jones D.N.C., Wood M., Reavill C., Scorer C.A., Worby A., Riley G., Eddershaw P., Ioannou C., Donati D., Hagan J.J., Ratti E.A. Studies towards the identification of a new generation of atypical antipsychotic agents. Bioorg. Med. Chem. Lett. 2007, 17:400-405.
71. Gee, A. D., Martarello, L., Johnson, C. N., and Witty, D. R. (2006). Preparation of isotopomeric piperazine-containing ligands labeling and diagnostic imaging of 5-HT6 receptors (17 pp.). WO Patent 2006053785.
72. 6, and 5-HT7. J. Med. Chem. 2003, 46:2795-2812.
73. 6 serotonin receptor binding of indolealkylamines, a preliminary structure-affinity investigation. Med. Chem. Res. 1999, 9:108-117.
74. 6 serotonin receptors. J. Med. Chem. 2000, 43:1011-1018.
75. 6 receptor ligands with a focus on arylsulfonyltryptamine analogs. Curr. Top. Med. Chem. 2010, 10:579-595.
76. Greenblatt, L. P. (2005). Preparation of piperidinylchromenylsulfonamides as 5-HT6 ligands (37 pp). WO Patent 2005037830.
77. Greenblatt, L. P. and Kelly, M. G. (2003). Preparation of 2-(aminoalkyl)chromans as 5-hydroxytryptamine-6 ligands for treatment of CNS disorders (63 pp.). WO Patent 2003029239.
78. Greenhouse, R., Harris, R. N. III, Jaime-Figueroa, S., Kress, J. M., Repke, D. B., and Stabler, R. S. (2006) Preparation of tetralin and indane derivatives and use as selective 5-HT6 and 5-HT2A receptor antagonists for treatment of CNS disorders (137 pp.). WO Patent 2006066748.
79. Gribble, A. D., Forbes, I. T., Lightfoot, A., Payne, A. H., and Walker, G. (2003a). Preparation of 7-phenylsulfonyl-tetrahydro-3-benzazepines as antipsychotic agents (33 pp.). WO Patent 2003099792.
80. Gribble, A. D., Forbes, I. T., Lightfoot, A., Payne, A. H., Walker, G., and Garzya, V. (2003b). Preparation of phenylsulfonyl substituted 3-benzazepines, isoquinolines and isoindoles as antipsychotic agents (76 pp.). WO Patent 2003099786.
81. 6 receptors. Neuropsychopharmacology 1999, 21:68S-76S.
82. Harris, R. N. III, Krauss, N. E., Kress, J. M., Repke, D. B., and Tabler, R. S. (2006). Preparation of Tetralin and Indane derivatives and use as 5-HT receptor antagonists targeting CNS disorders (47 pp.). WO Patent 2006066748.
83. Harris, R. N., Kress, J. M., Repke, D. B., and Stabler, R. S. (2007). Preparation of aryloxy quinolines as 5-HT6 receptor antagonists (19 pp.). US Patent 2007027161.
84. Harris, R. N. III, Repke, D. B., and Stabler, R. S. (2004). Preparation of quinolinone and benzoxazinone derivatives as 5-HT6 modulators (67 pp.). WO Patent 2004080969.
85. Haydar, S. N., Andrae, P. M., Yun, H., and Robichaud, A. J. (2010a). 1-(Arylsulfonyl)-4-(Piperazin-1-Yl)-1h-Benzimidazoles as 5-Hydroxytryptamine-6 Ligands (61 pp.). US Patent 2010120779.
86. 6 Receptor Antagonists. J. Med. Chem. 2010, 53:2521-2527.
87. 6 receptors in rat, pig and human brain tissue. Br. J. Pharmacol. 2000, 130:1597-1605.
88. 6 receptor ligands. J. Med. Chem. 2005, 48:1781-1795.
89. 6 receptor ligands as potential cognitive enhancers and antiobesity agents. Drug. Discov. Today. 2006, 11:283-299.
90. Hoyer D., Clarke D.E., Fozard J.R., Hartig P.R., Martin G.R., Mylecharane E.J., Saxena P.R., Humphrey P.P. International Union of Pharmacology classification of receptors for 5-hydroxytryptamine (Serotonin). Pharmacol. Rev. 1994, 46:157-203.
91. Hoyer D., Martin G.R. Classification and nomenclature of 5-HT receptors, a comment on current issues. Behav. Brain Res. 1996, 73:263-268.
92. 6 receptor antagonists. Bioorg. Med. Chem. Lett. 2000, 10:1719-1721.
93. 6 receptor antagonists. Bioorg Med. Chem. Lett. 2009, 19:3183-3187.
94. Jacobsen, E. J., and King, S. J. (2004). Preparation of piperazinyl- and diazepanylarylsulfones as serotonin 5-HT6 receptor ligands (23 pp.). US Patent 2004014966.
95. Jasti, V., Ramakrishna, V. S. N., Kambhampati, R. S., Shirsath, V. S., and Vishwottam, N. K. (2005). Preparation of pyrrolidinyl indoles as 5HT6 receptor modulators (52 pp.). WO Patent 2005066157.
96. Johansson, G., Jenmalm-Jensen, A., and Beierlein, K. (2003). Preparation of pyridino-fused heterocycles useful for the treatment of obesity, type II diabetes and CNS disorders (187 pp.). WO Patent 2004000828.
97. 6 receptor antagonists, prospects for the treatment of cognitive disorders including dementia. Curr. Opin. Drug. Discov. Devel. 2008, 11:642-654.
98. Johnson, C. N., Moss, S. F., and Witty, D. R. (2005a). Preparation of piperazinyl-quinoline derivatives useful for the treatment of CNS disorders (20 pp.). WO Patent 2005030724.
99. Johnson, C. N., Stemp, G., Thompson, M., and Witty, D. R. (2005b). 3-(Arylsulfonyl)quinolines as 5-HT6 receptor antagonists for the treatment of CNS disorders, and their preparation, pharmaceutical compositions, and use (26 pp.). WO Patent 2005030724.
100. Johnson, C. N., and Witty, D. R. (2005). Preparation of 8-(1-piperazinyl)quinolines for treatment of CNS disorders (33 pp.). WO Patent 2005026125.
101. Kelly, M. G., and Cole, D. C. (2004). Preparation of 1-alkylsulfonylheterocyclylbenzazoles and related compounds as 5-hydroxytryptamine-6 ligands (20 pp.). US Patent 2004192749.
102. Kelly M.G., Cole D.C. 1-Ayrl- or 1-alkylsufonyl-heterocyclylbenzazoles as 5-hydroxytryptamine-6 ligands. US Patent 2006, 7034029.
103. Kelly, M. G., Greenblatt, L. P., Zhang, G., Palmer, Y. L., and Lenicek, S. E. (2003). Preparation of 2-(aminoalkyl)chromans and benzofurans as 5-hydroxytryptamine-6 ligands for treatment of CNS disorders (70 pp.). WO Patent 2003029239.
104. 6 receptor antagonists reverse delay-dependent deficits in novel object discrimination by enhancing consolidation-an effect sensitive to NMDA receptor antagonism. Neuropharmacology 2004, 47:195-204.
105. 6 serotonin receptor and mutagenesis studies of the third cytoplasmic loop. Mol. Brain Res. 2001, 90:110-117.
106. 6 serotonin receptor. J. Neurochem. 1996, 66:47-56.
107. 6 receptors. Bioorg. Med. Chem. Lett. 2006, 16:5832-5835.
108. 6 serotonin receptors. Bioorg. Med. Chem. Lett. 2005, 15:1987-1991.
109. Krauss, N. E. and Zhao, S. -H. (2006). Preparation of chroman derivatives as 5-HT receptor ligands (43 pp.). WO Patent 2006066756.
110. 6 serotonin receptor binding affinities of N1-benzenesulfonyl and related tryptamines. Med. Chem. Res. 2000, 10:230-242.
111. 6 serotonin receptor ligands. Bioorg. Med. Chem. Lett. 2005, 15:1707-1711.
112. Li, Y., and Zhou, P. (2002). Preparation of heterocyclylalkoxy-, heterocyclylalkylthio- and heterocyclylalkylaminobenzazoles as 5-hydroxytryptamine-6 (5-HT6) ligands (51 pp.). WO Patent 2002085853.
113. 6 ligands. Bioorg. Med. Chem. Lett. 2008, 18:3929-3931.
114. 6 Ligands. Bioorg. Med. Chem. Lett. 2009, 19:2413-2415.
115. 6 ligands. Bioorg. Med. Chem. Lett. 2009, 19:3214-3216.
116. 6 ligands. Bioorg. Med. Chem. Lett. 2009, 19:1115-1117.
117. 6 Antagonists as Potential Treatment for Cognitive Dysfunction. Drug Dev. Res. 2009, 70:145-168.
118. 6 antagonists. J. Med. Chem. 2010, 10.1021/jm1007825.
119. 6 antagonists. Bioorg. Med. Chem. 2010, in press.
120. Maag, H., Sui, M., and Zhao, S.-H. (2004). Preparation of substituted benzoxazinones as selective 5-HT6 antagonists for treating central nervous system diseases and gastrointestinal tract disorders (40 pp.). US Patent 2004092512.
121. Madera, A. M., and Weikert, R. J. (2004a). Preparation of 2,4-substituted indoles as 5-HT6 modulators (38 pp.). WO Patent 2004026831.
122. Madera, A. M., and Weikert, R. J. (2004b). Preparation of 2,7-substituted indoles as 5-HT6 modulators (36 pp.). WO Patent 2004026830.
123. 6 receptor antagonist, SB-742457, in Alzheimer's disease. Curr. Alzheimer Res. 2010, 7:374-385.
124. Monsma F.J., Shen Y., Ward R.P., Hamblin M.W., Sibley D.R. Cloning and expression of a novel serotonin receptor with high affinity for tricyclic psychotropic drugs. Mol. Pharmacol. 1993, 43:320-327.
125. Murphy D.L., Andrews A.M., Wichems C.H., Li Q., Tohda M., Greenberg B. Brain serotonin neurotransmission: an overview and update with an emphasis on serotonin subsystem heterogeneity, multiple receptors, interactions with other neurotransmitter systems, and consequent implications for understanding the actions of serotonergic drugs. J. Clin. Psychiatry 1998, 59:4-12.
126. Nordvall, G., Petersson, C., Rakos, L., and Sohn, D. (2006). Novel 8-sulfonyl-3-amino-substituted chroman or tetrahydronaphthalene derivatives modulating the 5-HT6 receptor and their preparation and pharmaceutical compositions (144 pp.). WO Patent 2006126938.
127. Nordvall, G., Petersson, C., and Sehgelmeble, F. (2007). Benzoxazepinylbenzenesulfonamide and process for their preparation, intermediates, pharmaceutical compositions and their use in the treatment of 5-HT6 mediated disorders such as Alzheimer's disease, cognitive disorders, cognitive impairment associated with schizophrenia, obesity and Parkinson's disease (76 pp.). WO Patent 2007004960.
128. Nordvall, G., and Sehgelmeble, F. (2007). Benzoxazepinesulfonamides and process for their preparation, intermediates, pharmaceutical compositions and their use in the treatment of 5-HT6 mediated disorders such as Alzheimer's disease, cognitive disorders, cognitive impairment associated with schizophrenia, obesity and Parkinson's disease (44 pp.). WO Patent 2007004959.
129. Owens, T. D., Sethofer, S., Walker, K. A. M., and Zhao, S.-H. (2007). Preparation of benzimidazole derivatives as prodrugs treating 5-HT6 and 5-ht2 receptors (121 pp.). WO Patent 2007006677.
130. Pineiro-Nunez, M. M., Bauzon, D. D., Bymaster, F. P., Chen, Z., Chernet, E., Clay, M. P., Crile, R., DeLapp, N. W., Denny, C. P., Falcone, J. F., Flaugh, M. E., Heinz, L. J., Kiefer, A. D., Koch, D. J., Krushinski, J. H., Leander, J.R. DeLapp N.W. Denny C.P. Falcone J.F. Flaugh M.E. Heinz L.J. Kiefer A.D. Koch D.J. Krushinski J.H. Leander J.D. Lindstrom T.D. Liu B. McKinzie D.L. Ne D., Lindstrom, T. D., Liu, B., McKinzie, D. L., Nelson, D. L., Phebus, L. A., Rocco, V. P., Schaus, J. M., Wolff, M. C., and Ward, J. S. (2005). Discovery and SAR studies of 2,6-difluorobenzenesulfonic acid 1-methyl-3-(1-methylpiperidin-4-yl)-1H-indol-5-yl ester, a novel and potent 5-HT6 antagonist for the treatment of cognitive deficit. Abstracts of Papers, 229th ACS National Meeting, San Diego, CA, United States, March 13-17, MEDI-282.
131. 6 antagonist MS-245. Pharmacol. Biochem. Behav. 2004, 78:263-268.
132. 6 receptor ligand templates. Bioorg. Med. Chem. Lett. 2003, 13:3355-3359.
133. 6 serotonin receptors. Bioorg. Med. Chem. Lett. 2005, 15:5298-5302.
134. 6 receptors. Bioorg. Med. Chem. Lett. 2004, 14:4569-4573.
135. Putman, D. G. (2004). Preparation of 2,5- and 2,6-substituted tetrahydroisoquinolines as 5-HT6 modulators, in particular selective 5-HT6 antagonists, for treating CNS disorders (59 pp.). WO Patent 2004078176.
136. Rapport M.M., Green A.A., Page I.H. Serum vasoconstrictor (serotonin). IV. Isolation and characterization. J. Biol. Chem. 1948, 176:1243-1251.
137. 6 receptor antagonist. J. Med. Chem. 2003, 46:1273-1276.
138. Robichaud A.J. Approaches to palliative therapies for Alzheimer's disease. Curr. Top. Med. Chem. 2006, 6:553-568.
139. Robichaud, A. J. (2010). Identification of SAM-531 (WAY-262531), a selective 5-HT6 antagonist for the treatment of cognitive dysfunction associated with schizophrenia and Alzheimer's disease. Abstracts of Papers, 239th ACS National Meeting, San Francisco, CA, USA, March 21-25, MEDI-34.
140. 6 receptor antagonists enhance retention of a water maze task in the rat. Psychopharmacology 2001, 158:114-119.
141. Roth B.L., Craigo S.C., Choudhary M.S., Uluer A., Monsma F.J., Shen Y., Meltzer H.Y., Sibley D.R. Binding of typical and atypical antipsychotic agents to 5-hydroxytryptamine-6 and 5-hydroxytryptamine-7 receptors. J. Pharmacol. Exp. Ther. 1994, 268:1403-1410.
142. 6 receptor antagonist. Br. J. Pharmacol. 2000, 130:1606-1612.
143. 6) receptor: Molecular cloning, localization and stimulation of cAMP accumulation. Biochem. Biophys. Res. Commun. 1993, 193:268-276.
144. 6 receptor ligands. J. Med. Chem. 2001, 44:3881-3895.
145. 6 receptor agonists: WAY-181187 and WAY-208466. Neuropsychopharmacology 2008, 33:1323-1335.
146. 6 receptor antagonist RO4368554 in rat models for cognition and sensorimotor gating. Eur. Neuropsychopharmacol. 2007, 17:277-288.
147. Schumacher, R. A., Tehim, A., and Xie, W. (2010). Preparation of pyrrolo[3,2-b]pyridine compounds as 5-HT6 receptor modulators for treatment of CNS disorders. WO Patent 2010024980.
148. 6 receptor antagonists. Bioorg. Med. Chem. Lett. 2008, 18:738-743.
149. 6 serotonin receptors. J. Med. Chem. 2006, 49:5217-5225.
150. 6 antagonists. Bioorg. Med. Chem. Lett. 2009, 19:2409-2412.
151. 6 serotonin receptors. Bioorg. Med. Chem. Lett. 2006, 16:3793-3796.
152. Slassi, A., Edwards, L., O'Brien, A., Xin, T., and Tehim, A. (1999). Preparation of 3-(2-pyrrolidinylmethyl)indoles as 5-HT6 antagonists (55 pp). WO Patent 9947516.
153. Slassi, A., Edwards, L., O'Brien, A., Xin, T., and Tehim, A. (2000). Preparation of 1-(arylsulfonyl)-3-(tetrahydropyridinyl)indoles as 5-HT6 receptor inhibitors (22 pp.). US patent 6133287.
154. 6 receptor antagonists for the treatment of CNS diseases. Expert Opin. Ther. Pat. 2002, 12:513-527.
155. Sleight A.J., Boess F.G., Bos M., Levet-Trafit B., Bourson A. The 5-hydroxytryptamine-6 receptor: localization and function. Expert Opin. Ther. Pat. 1998, 8:1217-1224.
156. 6 receptors. Br. J. Pharmacol. 1998, 124:556-562.
157. 6 expression in the rat: functional studies using antisense oligonucleotides. Behav. Brain Res. 1996, 73:245-248.
158. 6 receptor antagonist. Pharmacol. Biochem. Behav. 2002, 71:645-654.
159. Sui, M., and Zhao, S.-H. (2005). A preparation of derivatives of piperazinylquinazolinone, benzothiadiazine, and benzooxazinone, useful as 5-HT6 and/or 5-HT2A antagonists (92 pp.). WO Patent 2005067933.
160. Tenbrink, R. E. (2001a). Preparation of 4-(aminoalkoxy)carbazoles for the treatment of central nervous (CNS) diseases (97 pp.). WO Patent 2001017963.
161. Tenbrink, R. E. (2001b). Preparation of oxazinocarbazoles as 5-HT6 serotonin receptor modulators (68 pp.). WO Patent 2001009142.
162. Tenbrink, R. E. and Kortum, S. W. (2003). Preparation of arylsulfones as 5-HT6 receptor modulators (57 pp.). WO Patent 2003072558.
163. 6 receptor antagonists. Bioorg. Med. Chem. Lett. 2008, 18:5698-5700.
164. 6 antagonists. Bioorg Med. Chem. Lett. 2000, 10:2295-2299.
165. 6 receptor ligands with therapeutic potential. Prog. Med. Chem. 2009, 48:163-224.
166. Xin, T., Isaac, M., and Slassi, A. (2001). Bicyclic amine derivatives of 1-arylsulfonyl indoles and indazoles, having 5-HT6 receptor antagonist activity (28 pp.). WO Patent 2001032660.
167. Zhao, S.-H. (2004). Preparation of aminoalkoxyindoles as 5-HT6-receptor ligands, in particular selective 5-HT6 antagonists, for treating CNS disorders (79 pp.). WO Patent 2004050085.
168. 6 receptor antagonists. Bioorg. Med. Chem. Lett. 2007, 17:3504-3507.
169. Zhou, P., Harrison, B. L., and Li, Y. (2002a). Preparation of heterocyclyloxy-, heterocyclylthioxy- and heterocyclylaminobenzazoles as 5-hydroxytryptamine-6 (5-HT6) ligands (51 pp.). WO Patent 2002085892.
170. Zhou, P., Kelly, M. G., and Li, Y. (2002b). Preparation of heterocyclylalkylindoles or -azaindoles as 5-hydroxytryptamine-6 ligands (55 pp.). WO patent 2002051832.
171. 6 receptor ligands. Bioorg. Med. Chem. Lett. 2005, 15:1393-1396.